Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
161.50    -11.00 (-6.38%)
Bid:
158.50
Ask:
162.50
Spread: 4.00 (2.524%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Director/PDMR Shareholding

15 Dec 2008 09:33

RNS Number : 1234K
Hutchison China Meditech Limited
15 December 2008
 



 

Hutchison China MediTech Limited ("Chi-Med") 

(AIM: HCM)

Director's Shareholding

LondonMonday, 15 December 2008: Chi-Med was informed on 12 December 2008 that Mr Christian HoggExecutive Director and Chief Executive Officer of Chi-Med, purchased 100,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of 40p each on 12 December 2008.

Following this purchase, Mr Hogg is beneficially interested in 270,000 Shares, representing approximately 0.5% of the current issued share capital of Chi-Med. This is in addition to the 576,136 vested options held by him, representing approximately 1.1% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients. 

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGCBDDBXBGGIU
Date   Source Headline
16th Oct 201311:58 amRNSDirector/PDMR Shareholding
9th Oct 20137:00 amRNSPayment From Janssen Pharmaceuticals
9th Oct 20137:00 amRNSLilly Deal for Fruquintinib
9th Oct 20137:00 amRNSAnalyst & Investor Briefing
3rd Oct 20137:00 amRNSAnalyst briefing on Chi-Med's R&D business
13th Sep 20132:21 pmRNSHolding(s) in Company
8th Aug 201312:05 pmRNSDirector/PDMR Shareholding
30th Jul 20137:00 amRNSInterim Results
17th Jul 20137:00 amRNSGlobal Phase III HPML-004 maintenance study starts
1st Jul 20137:00 amRNSBlocklisting Interim Review
25th Jun 20137:00 amRNSVolitinib Phase I triggers US$5 million milestone
24th Jun 20137:00 amRNSNotice of Results
10th May 201312:24 pmRNSResult of AGM
24th Apr 20137:00 amRNSGlobal Phase III UC trial initiated with HPML-004
12th Apr 20137:16 amRNSNutrition Science Partners JV Approved
9th Apr 20137:00 amRNS2012 Annual Report and Notice of AGM
8th Apr 20137:00 amRNSData Presentations at AACR
26th Mar 20137:00 amRNSFinal Results
28th Feb 20137:00 amRNSTotal Voting Rights
18th Feb 20137:00 amRNSNotice of Results
28th Jan 201311:15 amRNSHolding(s) in Company
31st Dec 20127:00 amRNSBlocklisting Six Monthly Return
28th Nov 20127:00 amRNSChi-Med and Nestle´ Health Science Joint Venture
1st Nov 20127:00 amRNSPhase I trial with EGFR inhibitor theliatinib
8th Oct 20127:00 amRNSTR1 Notification of major interest in shares
28th Sep 20121:42 pmRNSTotal Voting Rights
13th Sep 20122:16 pmRNSDirector's Shareholding
28th Aug 201211:21 amRNSChange of Nominated Adviser
31st Jul 20127:00 amRNSInterim Results
5th Jul 20129:08 amRNSTotal Voting Rights
29th Jun 20127:00 amRNSBlocklisting Interim Review
28th Jun 20127:00 amRNSNotice of Results
14th Jun 20121:33 pmRNSExercise of Options
6th Jun 20127:00 amRNSAnti-Cancer Clinical Data Presented at ASCO
30th May 20121:48 pmRNSDirector/PDMR Shareholding
11th May 201212:32 pmRNSResult of AGM
10th Apr 20127:00 amRNS2011 Annual Report and Notice of AGM
20th Mar 20127:00 amRNSFinal Results
22nd Feb 20127:00 amRNSNovel c-Met inhibitor Volitinib Enters the Clinic
20th Feb 20127:00 amRNSNotice of Results
14th Feb 20128:07 amRNSHolding(s) in Company
2nd Feb 20127:00 amRNSTotal Voting Rights
5th Jan 201210:49 amRNSHolding(s) in Company
29th Dec 20117:00 amRNSBlocklisting Six Monthly Return
21st Dec 20117:00 amRNSCANCER THERAPY COLLABORATION WITH ASTRAZENECA
12th Dec 20117:00 amRNSChi-Med Loan Facility
4th Nov 20117:00 amRNSInitiates Epitinib Phase I clinical study
5th Sep 20117:00 amRNSHolding(s) in Company
1st Aug 20117:00 amRNSInterim Results
22nd Jul 20117:00 amRNSChina Healthcare Division expansion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.